Dual GIP/GLP-1 Receptor Agonists
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Overview
Dual GIP/GLP-1 receptor agonists activate two incretin hormone receptors at once — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Tirzepatide is the first drug in this class, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea.
How do dual gip/glp-1 receptor agonists work?
Simultaneous agonism of the GIP and GLP-1 receptors enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite — producing greater glycemic and weight effects than GLP-1 receptor agonism alone.
Drugs in this class
- Tirzepatide (Mounjaro, Zepbound)
- Tirzepatide (Mounjaro) (Mounjaro)
- Tirzepatide (Zepbound) (Zepbound)